BFEC
HEPA

Benjamin F. Edwards & Company’s Hepion Pharmaceuticals HEPA Stock Holding History

Benjamin F. Edwards & Company’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Hold
0
– – – 2184
2024
Q1 		– Hold
0
– – – 2165
2023
Q4 		– Hold
0
– – – 2116
2023
Q3 		– Hold
0
– – – 1773
2023
Q2 		– Hold
0
– – – 1796
2023
Q1 		– Sell
-1
Closed -$739 – 1841
2022
Q4 		$0 Hold
1
– – ﹤0.01% 1866
2022
Q3 		$1K Hold
1
– – ﹤0.01% 1761
2022
Q2 		$1K Sell
1
-4
-80% -$3.33K ﹤0.01% 1747
2022
Q1 		$6K Hold
5
– – ﹤0.01% 1479
2021
Q4 		$5K Sell
5
-2
-29% -$2.74K ﹤0.01% 1527
2021
Q3 		$10K Hold
7
– – ﹤0.01% 1375
2021
Q2 		$13K Buy
7
+4
+133% +$7.32K ﹤0.01% 1314
2021
Q1 		$6K Buy
+3
New +$6.58K ﹤0.01% 1466
2020
Q4 		– Hold
0
– – – 1662
2020
Q3 		– Hold
0
– – – 1706
2020
Q2 		– Hold
0
– – – 1722
2020
Q1 		– Hold
0
– – – 1781
2019
Q4 		– Hold
0
– – – 1903
2019
Q3 		– Hold
0
– – – 1887
2019
Q2 		– Hold
0
– – – 1934

Other funds holding HEPA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Benjamin F. Edwards & Company's HEPA Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Hepion Pharmaceuticals (HEPA) position steady in Q2 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Benjamin F. Edwards & Company first reported a position in HEPA in Q1 2021 and has held it in 8 quarters since. The position peaked at $13K in Q2 2021. 18 funds tracked by Wall St. Rank hold HEPA as of Q2 2024.

  • Benjamin F. Edwards & Company held 0 shares of Hepion Pharmaceuticals worth $0 as of Q2 2024.
  • Benjamin F. Edwards & Company left its Hepion Pharmaceuticals share count unchanged in Q2 2024.
  • Hepion Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2184 holding.
  • Benjamin F. Edwards & Company first reported a position in Hepion Pharmaceuticals in Q1 2021 and has held it in 8 quarters since.
  • Benjamin F. Edwards & Company's Hepion Pharmaceuticals position peaked at $13K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.